Identification	O
of	O
focally	O
amplified	O
lineage	O
-	O
specific	O
super	O
-	O
enhancers	O
in	O
human	O
epithelial	O
cancers	O
.	O


Whole	O
-	O
genome	O
analysis	O
approaches	O
are	O
identifying	O
recurrent	O
cancer	O
-	O
associated	O
somatic	O
alterations	O
in	O
noncoding	O
DNA	O
regions	O
.	O


We	O
combined	O
somatic	O
copy	O
number	O
analysis	O
of	O
12	O
tumor	O
types	O
with	O
tissue	O
-	O
specific	O
epigenetic	O
profiling	O
to	O
identify	O
significant	O
regions	O
of	O
focal	O
amplification	O
harboring	O
super	O
-	O
enhancers	O
.	O


Copy	O
number	O
gains	O
of	O
noncoding	O
regions	O
harboring	O
super	O
-	O
enhancers	O
near	O
KLF5	O
,	O
USP12	O
,	O
PARD6B	O
and	O
MYC	O
are	O
associated	O
with	O
overexpression	O
of	O
these	O
cancer	O
-	O
related	O
genes	O
.	O


We	O
show	O
that	O
two	O
distinct	O
focal	O
amplifications	O
of	O
super	B-ENHANCER
-	I-ENHANCER
enhancers	I-ENHANCER
3	I-ENHANCER
'	I-ENHANCER
to	I-ENHANCER
MYC	I-ENHANCER
in	I-ENHANCER
lung	I-ENHANCER
adenocarcinoma	E-ENHANCER
(	O
MYC	B-ENHANCER
-	I-ENHANCER
LASE	E-ENHANCER
)	O
and	O
endometrial	O
carcinoma	O
(	O
MYC	B-ENHANCER
-	I-ENHANCER
ECSE	E-ENHANCER
)	O
are	O
physically	O
associated	O
with	O
the	O
MYC	O
promoter	O
and	O
correlate	O
with	O
MYC	O
overexpression	O
.	O


CRISPR	O
/	O
Cas9	O
-	O
mediated	O
repression	O
or	O
deletion	O
of	O
a	O
constituent	O
enhancer	B-ENHANCER
within	I-ENHANCER
the	I-ENHANCER
MYC	I-ENHANCER
-	I-ENHANCER
LASE	I-ENHANCER
region	E-ENHANCER
led	O
to	O
significant	O
reductions	O
in	O
the	O
expression	O
of	O
MYC	O
and	O
its	O
target	O
genes	O
and	O
to	O
the	O
impairment	O
of	O
anchorage	O
-	O
independent	O
and	O
clonogenic	O
growth	O
,	O
consistent	O
with	O
an	O
oncogenic	O
function	O
.	O


Our	O
results	O
suggest	O
that	O
genomic	O
amplification	O
of	O
super	O
-	O
enhancers	O
represents	O
a	O
common	O
mechanism	O
to	O
activate	O
cancer	O
driver	O
genes	O
in	O
multiple	O
cancer	O
types	O
.	O
